TY - BOOK ID - 145065745 TI - Malignant Mesothelioma AU - L. Pouliquen, Daniel AU - Kopecka, Joanna PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - well-differentiated papillary mesothelioma KW - WDPM KW - malignant mesothelioma KW - DNA sequencing KW - mutation KW - mesothelioma KW - tumor suppressor KW - targeted therapy KW - immunotherapy KW - biomarkers KW - proteomics KW - macrophage-capping protein KW - fatty acid-binding protein KW - laminin subunit beta-2 KW - selenium-binding protein 1 KW - carcinogenesis KW - malignant pleural mesothelioma KW - asbestos exposure KW - DNA methylation KW - lymphocyte-to-monocyte ratio KW - epigenome-wide analysis KW - survival analysis KW - metabolomics KW - radiotherapy KW - cancers KW - inflammation KW - infiltrating immune cells KW - prognostic biomarker KW - predictive biomarker KW - immune therapy KW - VATS KW - extrapleural pneumonectomy KW - pleurectomy decortication KW - therapy response KW - survival KW - FDG KW - PET-CT KW - mesothelium KW - oxidative stress KW - redox-sensitive factors KW - asbestos KW - carbon nanotubes KW - protein-protein interactions KW - systems biology KW - network analysis KW - drug repurposing KW - pleural mesothelioma KW - gene expression KW - immunogenicity KW - sarcomatoid KW - epithelioid KW - first line KW - meta-analysis KW - systematic review KW - MPM KW - lurbinectedin KW - DNA damage response KW - histotype KW - Hippo pathway KW - NF2 KW - BAP1 KW - CDKN2A KW - PTCH1 KW - SETD2 KW - MTAP KW - liquid biopsies KW - circulating tumor DNA KW - plasma KW - cancer-specific mutations KW - genomics KW - cancer biomarkers KW - tumor microenvironment KW - tumor-associated macrophages KW - dendritic cells KW - immunohistochemistry KW - interaction analysis KW - pleural effusion KW - well-differentiated papillary mesothelioma KW - WDPM KW - malignant mesothelioma KW - DNA sequencing KW - mutation KW - mesothelioma KW - tumor suppressor KW - targeted therapy KW - immunotherapy KW - biomarkers KW - proteomics KW - macrophage-capping protein KW - fatty acid-binding protein KW - laminin subunit beta-2 KW - selenium-binding protein 1 KW - carcinogenesis KW - malignant pleural mesothelioma KW - asbestos exposure KW - DNA methylation KW - lymphocyte-to-monocyte ratio KW - epigenome-wide analysis KW - survival analysis KW - metabolomics KW - radiotherapy KW - cancers KW - inflammation KW - infiltrating immune cells KW - prognostic biomarker KW - predictive biomarker KW - immune therapy KW - VATS KW - extrapleural pneumonectomy KW - pleurectomy decortication KW - therapy response KW - survival KW - FDG KW - PET-CT KW - mesothelium KW - oxidative stress KW - redox-sensitive factors KW - asbestos KW - carbon nanotubes KW - protein-protein interactions KW - systems biology KW - network analysis KW - drug repurposing KW - pleural mesothelioma KW - gene expression KW - immunogenicity KW - sarcomatoid KW - epithelioid KW - first line KW - meta-analysis KW - systematic review KW - MPM KW - lurbinectedin KW - DNA damage response KW - histotype KW - Hippo pathway KW - NF2 KW - BAP1 KW - CDKN2A KW - PTCH1 KW - SETD2 KW - MTAP KW - liquid biopsies KW - circulating tumor DNA KW - plasma KW - cancer-specific mutations KW - genomics KW - cancer biomarkers KW - tumor microenvironment KW - tumor-associated macrophages KW - dendritic cells KW - immunohistochemistry KW - interaction analysis KW - pleural effusion UR - https://www.unicat.be/uniCat?func=search&query=sysid:145065745 AB - Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. ER -